06
Apr
2010
Posted in I - Series C, Q - 1Q10, R - INTERNATIONAL, X - HPV, X - Oncology, X - THx, X - Vaccines
Genticel (France) a clinical-stage biopharmaceutical company focused on therapeutic vaccines for the prevention of cervical cancer in HPV infected women, closed a $17.7M Series C financing. Participants include AGF Private Equity, Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio Fund and Edmond de Rothschild Investment Partners.